Your browser doesn't support javascript.
loading
YM155 inhibits topoisomerase function.
Hong, Mei; Ren, Ming-Qiang; Silva, Jeane; Paul, Ananya; Wilson, W David; Schroeder, Carsten; Weinberger, Paul; Janik, John; Hao, Zhonglin.
Afiliação
  • Hong M; aCancer Center, Georgia Regents University Cancer Center bDepartment of Surgery cDepartment of ENT Surgery, Center for Biotechnology and Genomic Medicine dDepartment of Medicine, Medical College of Georgia, Augusta eDepartment of Chemistry, Georgia State University, Atlanta, Georgia, USA.
Anticancer Drugs ; 28(2): 142-152, 2017 02.
Article em En | MEDLINE | ID: mdl-27754993
ABSTRACT
YM155 (sepantronium bromide) has been evaluated in clinical trials as a survivin suppressant, but despite positive signals from early work, later studies were negative. Clarification of the mechanism of action of YM155 is important for its further development. YM155 affects cells in a cell cycle-specific manner. When cells are in G1, YM155 prevented their progression through the S phase, leaving the cells at G1/S when exposed to YM155. Passage through mitosis from G2 is also defective following YM155 exposure. In this study, YM155 did not behave like a typical DNA intercalator in viscosity, circular dichroism, and absorption spectroscopy studies. In addition, molecular modeling experiments ruled out YM155 DNA interaction to produce DNA intercalation. We show that YM155 inhibited topoisomerase 2α decatenation and topoisomerase 1-mediated cleavage of DNA, suggesting that YM155 inhibits the enzyme function. Consistent with these findings, DNA double-strand break repair was also inhibited by YM155.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Naftoquinonas / Inibidores da Topoisomerase / Imidazóis / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Anticancer Drugs Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Naftoquinonas / Inibidores da Topoisomerase / Imidazóis / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Anticancer Drugs Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos